Piper Sandler Issues Pessimistic Forecast for Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock Price

Amphastar Pharmaceuticals (NASDAQ:AMPH) had its price target lowered by Piper Sandler from $36.00 to $32.00 in a research note issued to investors on Friday,Benzinga reports. The firm currently has a “neutral” rating on the stock. Piper Sandler’s target price would suggest a potential upside of 13.11% from the company’s current price.

Separately, Wells Fargo & Company began coverage on Amphastar Pharmaceuticals in a research report on Friday, November 22nd. They issued an “equal weight” rating and a $55.00 target price for the company.

Amphastar Pharmaceuticals Stock Performance

Shares of AMPH stock opened at $28.29 on Friday. Amphastar Pharmaceuticals has a 12 month low of $25.89 and a 12 month high of $53.96. The stock has a market cap of $1.35 billion, a PE ratio of 9.43, a price-to-earnings-growth ratio of 2.19 and a beta of 0.77. The company has a current ratio of 3.43, a quick ratio of 2.61 and a debt-to-equity ratio of 0.82. The company’s fifty day moving average price is $31.91 and its 200-day moving average price is $40.52.

Insider Buying and Selling at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 4,231 shares of the business’s stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $27.54, for a total transaction of $116,521.74. Following the completion of the sale, the chief financial officer now directly owns 97,363 shares in the company, valued at $2,681,377.02. The trade was a 4.16 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 27.10% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in AMPH. Pacer Advisors Inc. grew its stake in shares of Amphastar Pharmaceuticals by 51,977.4% during the 4th quarter. Pacer Advisors Inc. now owns 1,350,368 shares of the company’s stock valued at $50,139,000 after acquiring an additional 1,347,775 shares during the period. Boston Trust Walden Corp raised its holdings in shares of Amphastar Pharmaceuticals by 81.4% during the 4th quarter. Boston Trust Walden Corp now owns 978,920 shares of the company’s stock worth $36,347,000 after acquiring an additional 439,281 shares in the last quarter. Boston Partners purchased a new stake in shares of Amphastar Pharmaceuticals during the 4th quarter worth approximately $15,778,000. Wealthfront Advisers LLC purchased a new stake in shares of Amphastar Pharmaceuticals during the 4th quarter worth approximately $9,268,000. Finally, Systematic Financial Management LP purchased a new stake in shares of Amphastar Pharmaceuticals during the 4th quarter worth approximately $9,147,000. 65.09% of the stock is currently owned by institutional investors.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.